A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Prexasertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 22 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 03 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 16 Sep 2017 The study has been completed in Germany